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Prediction of cardiovascular (CV) complications represents
the Achilles’ heel of end-stage renal disease. Surrogate
markers of endothelial dysfunction have been advocated as
predictors of CV risk in this cohort of patients. We have
recently adapted a noninvasive laser Doppler flowmetry
(LDF) functional testing of endothelium-dependent
microvascular reactivity and demonstrated that end-stage
renal disease patients are characterized by profound
alterations in thermal hyperemic responsiveness. We
hypothesized that such functional assessment of the
cutaneous microcirculation may offer a valid, noninvasive
test of the severity of endothelial dysfunction and CV risk. To
test this hypothesis, we performed a cross-sectional study, in
which we compared LDF measurements to conventional risk
factors, and performed a pilot longitudinal study. LDF studies
were performed in 70 patients and 33 controls. Framingham
and Cardiorisk scores were near equivalent for low-risk
patients, but more divergent as risk increased. C reactive
protein (CRP) levels and LDF parameters (amplitude of
thermal hyperemia (TH), area under the curve of TH) showed
significant abnormality in high-risk vs low-risk patients
calculated using either Framingham or Cardiorisk scores.
Patients who had abnormal LDF parameters showed
increased CV mortality, however, had similar risk assessments
(Framingham, Cardiorisk, CRP, and homocysteine) to those
with unimpaired LDF tracings. In conclusion, LDF parameters
of microvascular reactivity offer a sensitive characterization
of endothelial dysfunction, which may improve CV risk
assessment through incorporation into the Framingham or
Cardiorisk algorithm.
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Epidemiological evidence has firmly established the link
between end-stage renal disease (ESRD) and cardiovascular
(CV) disease.1,2 Mechanistically this linkage depends on
widespread microvascular endothelial cell dysfunction (ECD)
in patients with ESRD leading inexorably to CV disease. Early
detection of ECD in ESRD is therefore central to determining
patient risk. Until recently, such detection has depended on
algorithms using surrogate markers of ECD. Examples of
surrogate markers include elevated levels of C reactive
protein (CRP), homocysteine, circulating selectins, plasmi-
nogen activator-1, and asymmetric dimethylarginine.3–7
While useful, markers often fail to provide direct evidence
of microvascular ECD but rather furnish indirect correlative
information.
For this reason, we have adopted laser Doppler flowmetry
(LDF) techniques of noninvasive assessment of cutaneous
blood flow. Cutaneous microvascular dysfunction parti-
cipates in ECD in a variety of disease states including
hypertension, insulin resistance, cardiac allograft vasculo-
pathy, and advanced diabetic retinopathy. LDF measurements
correlate well with angiographically demonstrated coronary
artery disease (CAD) (in review Stewart et al.8).
Using an array of parameters obtained from reactive
hyperemic and local thermal hyperemic challenges, we have
recently obtained data showing abnormal co-clustering of
parameters of LDF in ESRD patients with clinically evident
CAD and diabetes mellitus (DM).8 We have therefore
proposed that such functional assessments of the cutaneous
microcirculation may offer a valid, noninvasive test of the
severity of endothelial dysfunction and CV risk. To test this
hypothesis, we performed a cross-sectional study in which
we compared LDF measurements to conventional risk
factors. Specifically, the Framingham risk assessment score
has been proposed for predicting the CV risk in the general
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population.4,9 In addition, we compared LDF data to a
recently modified algorithm, Cardiorisk,10 which has been
advocated as a more accurate estimator of CV risk, though
neither has been tested in ESRD. Our current data indicate
that LDF indices closely correlate with the predictive risk of
CV complications in this particularly vulnerable cohort of
patients. Also, we performed a pilot limited longitudinal
study of this group of patients, the results of which suggested
that LDF abnormalities characteristic of ECD were more
sensitive predictors of ensuing CV disease than other tested
predictors.
RESULTS
Comparison of Framingham and Cardiorisk 10-year risk
assessment
We performed a comparative analysis of CV risk in the cohort
of ESRD patients, which were examined using LDF. As shown
in Figure 1, the majority of our patients, and in particular
those at the lower end of the risk spectrum, scored similarly
using Framingham and Cardiorisk (10-year) scoring systems.
However, for patients receiving higher risk scores, there was
an increased disparity between these two methods, with a
tendency towards the higher risk scores obtained using the
Cardiorisk algorithm than the Framingham scoring system.
Comparison of risk assessment and surrogate markers
of CV risk
Elevated CRP and hyperhomocysteinemia have been pro-
posed as independent risk factors.4 Therefore, we compared
the levels of CRP and homocysteine with the calculated risk
obtained using each of these two methods. Patients were
ranked according to their CV risk and separated about the
median into low- and high-risk groups for each set of risk
criterion. The high-risk group had elevated CRP values,
which did not reach significance by Framingham criteria
but were significant (Po0.05, Figure 2) using Cardiorisk
(10-year) system. CRP also differed between risk groups
when plotted against the Cardiorisk cumulative lifetime
risk (0.7670.2 low-risk vs 2.1770.9 high-risk, Po0.05, data
not shown). Homocysteine levels were not different between
high- and low-risk groups using Framingham or Cardiorisk.
However, only four of the studied patients, all in the ‘low-
risk’ group, had normal homocysteine levels.
LDF as a predictor of CV risk
Data were compared between high- and low-risk groups as
outlined above for 10-year risk scores. Postocclusive reactive
hyperemia data did not correlate with risk using either
Framingham or Cardiorisk. However, thermal hyperemia
(TH) parameters were well correlated with the calculated CV
risk. The amplitudes of each of the first and second thermal
peak and the intervening nadir were significantly decreased
(Po0.05) in the high Framingham risk population
(84.6717.4, 129.2721.6, and 38.9710.3 vs 57.8710.6,
92.0716.8, and 16.573.0, respectively) (Figure 3). Similar
findings appeared using Cardiorisk (Figure 4). However, only
the amplitude of the nadir achieved statistical significance
(37.5710.4 vs 17.973.4, Po0.05). Also, the area under the
TH curve was significantly decreased in the high-risk groups
using either Framingham (146 020727 435 vs 84 6077
15 447, Po0.05) or Cardiorisk (140 908727 888 vs 89 4357
9510, P¼ 0.001) as shown in Figure 5. Additionally, the area
under the TH curve was compared with risk using linear
regression over the entire risk spectrum and correlated
significantly with the Framingham risk score (P¼ 0.01) but
not with Cardiorisk (Figure 6). The lifetime risk score using
Cardiorisk did not correlate with any of the collected LDF
data.
LDF data were also analyzed for correlation with homo-
cysteine and CRP levels. Linear regression failed to demons-
trate a statistically significant relation between any one of the
laser Doppler flow parameters and either of these markers.
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Figure 1 | Comparison of risk assessment scores using the
Framingham and Cardiorisk criteria (R2¼ 0.575). Values at lower
portion of risk spectrum were almost equivalent when calculated
using either method. At the higher portion of risk spectrum, there
was a tendency for Cardiorisk to produce a higher estimate than
Framingham risk assessment. Results are shown as 10-year risk (%).
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Figure 2 | CRP and homocysteine levels in ESRD patients with
high and low CV risk. Risk was calculated using both (a and b)
Cardiorisk and (c and d) Framingham and patients were assigned
low- or high-risk category based on the binary conversion at the
median. Results are shown as mean7s.e.
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Figure 4 | Laser Doppler flow data and risk calculated using Cardiorisk. (a–c) No significant differences were noted between the groups
during postocclusion reactive hyperemia. (d–f) High-risk patients (above the median) had prolonged times to each thermal peak and the nadir,
similar to the results seen with Framingham (Figure 3). (g–i) The amplitude of thermal hyperemic peaks and nadir were diminished in high-risk
patients, but only the amplitude of nadir achieved significance.
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Figure 3 | Parameters of LDF and risk calculated using the Framingham criteria. (a–c) Postocclusion (PO) measurements were not
significantly different between these groups. (d–f) High-risk patients (above the median) had prolonged times to reach the thermal peaks and
the nadir although the differences were not significant. High-risk patients had significantly diminished amplitudes for the (g) first heat peak, (h)
heat nadir, and (i) second heat peak.
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The combined predictive ability of the surrogate markers
and LDF data was assessed by receiver operating character-
istic (ROC) curves using mROC,7 calculating the linear
combination that maximizes the area under the ROC curve
for each 2- and 3- parameter combinations, as well as for the
combination of all of the parameters. The largest area under
ROC curve for both Cardiorisk (10-year) and Framingham
was found by combining all of the collected data (Figure 7).
The area under the curve was 0.802 for both Cardiorisk and
Framingham with 95% confidence intervals (CI) of 0.5–0.810
(Cardiorisk score) and 0.5–0.816 (Framingham score).
Ten-year risk using LDF and Cardiorisk. The strongest
predictors of actual risk using Cardioriskþ LDF were CRP
and area under the heat curve that, when combined, had an
area under ROC curve of 0.748 (CI 0.609–0.84). A number of
additional parameters, when combined with CRP and area
under the heat curve, offered modest improvements to area
under the ROC curve up to 0.764 (CI 0.614–0.848).
Ten-year risk using LDF and Framingham. Using Framin-
ghamþ LDF system to assess risk, the best predictors were
CRP, amplitude of second heat peak and area under the heat
curve in combination. The single best pairing to predict risk
was amplitude of second heat peak and area under the heat
curve that had a ROC area of 0.725 (CI 0.58–0.82). Combining
this pair with numerous third parameters modestly improved
the ROC area up to 0.751 (CI 0.596–0.837).
Lifetime risk. The area under ROC curve for the lifetime
risk (Cardiorisk system) was smaller than using 10-year risk
(0.758 with CI of 0.5–0.747). The parameters with the
greatest contribution to predicting lifelong risk were the area
under the curve for reactive and TH, which combined for an
area of 0.706 (CI 0.554–0.806).
Subgroup analysis and patient prognosis
We previously demonstrated that abnormalities in LDF
parameters cosegregated with ESRD, CAD, and DM.8 Of
particular interest was that a large number of ESRD patients
with no known CAD or DM had LDF findings similar to
those of patients that did have CV complications. We
therefore examined whether the LDF parameters correlated
with increased risk using Framingham, Cardiorisk, CRP, or
homocysteine. The patients were grouped relative to the
median for area under the TH curve, as this parameter had
the strongest relationship with risk as outlined above. (The
same result was obtained when mean values were used.) As
seen in Figure 8, the patients with abnormal LDF parameters
had higher risk scores using both Framingham and
Cardiorisk, although neither result was statistically signifi-
cant. CRP levels were somewhat lower in this low perfusion
group, while homocysteine levels were equal, and neither of
these parameters showed statistically significant differences
between the groups.
We next compared patients grouped by increasing
expected severity of endothelial dysfunction into three
groups: those with neither CAD nor DM, those with CAD
or DM, and those with both CAD and DM. Results are
shown (Figure 9) for their risk assessment, surrogate markers,
and LDF parameters. Framingham risk increased with
severity, Cardiorisk had an unexpectedly low score for the
CADþDM group. CRP levels in the CADþDM were
elevated compared to the other two groups although not
significantly. Homocysteine levels were not different between
the groups. On the other hand, LDF parameters of ECD
demonstrated significant and progressive differences, as
shown in Figure 8. ESRD patients who died due to CV
causes invariably had abnormal LDF parameters 1–2 years
earlier, particularly the amplitude of the first and second
thermal peaks, which was two- to three-fold lower than in the
surviving population (Figure 10), despite the fact that all
other surrogate markers were comparable in both groups.
Furthermore, Mann–Whitney analysis showed that the nadir,
the amplitude of the postocclusive hyperemic response and
the postocclusive recruitment of capillaries into the hypemic
response contributed to the outcomes. Specifically, (1) CV
mortality was associated with the decreased amplitude of
the first thermal peak and the nadir (significant at P¼ 0.041
and 0.045, respectively), (2) development of congestive heart
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Figure 5 | Thermal hyperemia and cardiovascular risk. The area
under the curve (AUC) of TH compared with CV risk using (a)
Framingham and (b) Cardiorisk. Using either criterion the higher-risk
patients had markedly diminished area under the curve (AUC)
(mean7s.e).
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Figure 6 | Regression model of LDF and CV risk. Area under the TH
curve for the first 30 min of heating is plotted vs 10-year risk (%)
calculated using the Framingham criteria (R2¼ 0.085). The results
were analyzed using linear regression analysis.
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failure was associated with the same parameters (significant
at P¼ 0.017 and 0.038, respectively), and (3) development
of coronary heart disease was associated with the post-
occlusive recruitment of dermal capillaries (significant at
P¼ 0.016).
DISCUSSION
Our data demonstrate co-segregation of abnormal LDF
parameters with calculated increased CV risk using either
Framingham or Cardiorisk indices in ESRD patients. We
CR
P 
(m
g/l
)
Fr
a
m
in
gh
am
Ca
rd
io
ris
k
0
2
4
6
0
Low perfusion High perfusion Low perfusion High perfusion
Low perfusion High perfusionLow perfusion High perfusion
2
4
5
3
1
6
0
2
4
5
3
1
6
7
8
8
10
12
0
5
10
15
H
om
oc
ys
te
in
e
20
30
25
a b
c d
Figure 8 | ESRD patients with abnormal LDF parameters and
without known CV disease. The subset of ESRD patients with no
known history of CAD or DM was grouped according to the results of
their LDF study. The patients whose area under the TH curve was
lower than the median were grouped as ‘low perfusion’. Those
patients above the median were termed ‘high perfusion’. Low
perfusion patients had somewhat increased risk assessments using
both the (a) Cardiorisk and (b) Framingham criteria, although the
differences were not significant. No statistically significant differences
in (c) CRP levels or (b) homocysteine levels existed between low- and
high-perfusion groups.
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Cardiorisk Framingham CRP (mg/l ×10) HC (mol/l)
P<0.05
P<0.005
P<0.0001
P<0.05
P<0.05
P<0.05
P<0.05
P<0.01
P<0.01
P=0.0001
No CAD or DM
CAD or DM
CAD+DM
0
5
10
15
20
25
30
35
10
-Y
e
a
r 
ris
k 
(%
)
0
2
4
6
8
10
12
14
16
18
0
50
100
150
200
250
300
350
400
PO
time (s)
HP1
time (s)
HP1
amp
(a.u.)
HP2
time
(s/10)
Heat
area
(/1000)
HP2
amp
(a.u.)
Nadir
time (s)
Nadir
amp
(a.u.)
PO
amp
(a.u.)
PO
area
(/10)
a
c
b
Figure 9 | Risk assessment in ESRD patients with and without
known CV disease. Patients were grouped according to their history
of known CAD and or DM; these groups were then compared with (a)
Cardiorisk and Framingham risk assessment, (b) CRP and homo-
cysteine levels‘, and (c) LDF parameters. Varying levels of statistical
significance were achieved for these comparisons, as indicated.
Certain values (CRP, postocclusion area, time to thermal peak 2, and
the area under the TH curve) were modified as indicated to fit the
ordinate. HC¼ homocysteine, PO¼ Post Occlusion,
Amp¼ amplitude, HP1/HP2¼ first and second heat peaks.
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have also shown that LDF parameters of endothelial function
contain information, which is independent of risk indices.
In addition, when combined with risk scores enhances our
ability to predict future CV risk or death in those ESRD
patients. LDF parameters of microvascular ECD are of
prognostic value in a significant proportion of ESRD patients
free of known manifestations of CV disease. However, many
findings while consistent failed to reach statistical significance
underscoring the pilot and relatively weakly powered nature
of the present study and pointing towards the need for a
larger better powered study, which is currently underway.
One interesting negative finding was relatively poor co-
clustering of CRP and homocysteine levels with the patients
at higher CV risk. While there was no linear relationship,
there was some tendency for the higher risk population to
have elevated CRP levels. Also, homocysteine levels in our
ESRD patients were almost uniformly elevated, and therefore
no correlation between these values and the risk assessment
scores was noted. Future studies will use the high-sensitivity
CRP, which should better reveal such a relationship with LDF
markers and with overall risk.
The question of defining high-risk in ESRD deserves
special consideration. The consensus cutoff at 10% has been
widely used with Framingham score,4 but its applicability to
ESRD patients has not been demonstrated. Cardiorisk scores
are numerically higher than those obtained with Framing-
ham system. High risk cutoff remains controversial especially
for ESRD patients In the current study, we used several
approaches to convert risk assessment to binary parameters:
(a) applied 10% risk cutoff for both; (b) estimated an average
Cardiorisk cutoff point of 13% that corresponds to the 10%
consensus Framingham risk; (c) used the median value for
each risk assessment as a cutoff point. While the level of
significance varied between these methods, the trends
observed between the high- and low-risk groups followed
the same patterns regardless of the method.
Having adapted these Framingham and Cardiorisk risk
estimators to our patient population facilitated comparison
with LDF data. The high-risk population was characterized by
a markedly diminished local thermal hyperemic response. This
was evident at all measured data points: initial heat peak, heat
nadir, and second heat peak. Statistically, the differences
between the high- and low-risk groups were more significant
using the Framingham criteria than the Cardiorisk system. The
area under the curve for 30 min of heating was a particularly
robust LDF measure of CV risk and is also computationally
robust being relatively insensitive to artifact and timing.
Combining measured LDF parameters with Framingham
or Cardiorisk estimators to form ROC curves improved the
ability to predict CV risk in our ESRD population.
Framingham or Cardiorisk systems were equivalent, and
the ability of each system to predict CV morbidity and
mortality was enhanced by the addition of LDF parameters.
One limitation of the study was that it focused exclusively
on ESRD patients. ECD is present in a large percentage of
patients with ESRD. This may limit the importance of the
additional information provided by our noninvasive tech-
nology. ESRD is implicitly defined by the need for dialysis
and corresponds to K/DOQI stage 5(2). If ECD is near-
universal in this cohort, then prediction has a limited value.
For that reason, we will extend our patient base to include a
subset of chronic kidney disease patients without end-stage
disease corresponding to K/DOQI stages 3 and 4.
In conclusion, this study has provided several important
insights into CV risk assessment. First, Cardiorisk scoring
system predicts a higher risk than Framingham, although the
predictive value of each, based on ROC curve, is equivalent in
ESRD. Second, surrogate markers of risk, such as CRP,
correlate with increased risk within the ESRD population and
should be incorporated in future risk assessment criteria.
Homocysteine, despite its usefulness in the general popula-
tion, appears to be more uniformly elevated in ESRD, and is
thus not useful in predicting risk. Other markers of risk are
currently under investigation and will be included in future
studies. Finally, laser Doppler flow study has been shown to
be a valid marker a CV risk: abnormal LDF parameters
co-cluster with the presence or absence of ESRD, diabetes,
and known coronary disease,8 and have now been shown to
correlate with several predictors of CV risk. An important
aspect of the study has emerged during our subgroup analysis
of ESRD patients with no known coronary disease or
diabetes. One-half of these patients exhibit aberrant LDF
parameters similar to those seen in ESRD patients with
known CAD and/or DM. Despite this distinction in LDF
parameters, all other risk assessment methods utilized in this
study failed to indicate a difference between these groups,
whereas LDF abnormalities are associated with significantly
increased CV mortality. Abnormal LDF parameters are
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sensitive indicators of an increased CV risk, which, in
combination with conventional risk systems, provide en-
hanced prognostic information concerning CV disease in
ESRD. Further diagnostic and prognostic validation of this
noninvasive test of microvascular endothelial dysfunction will
require a longitudinal prospective study of ESRD patients.
MATERIALS AND METHODS
Subjects and experimental outline
The study had a two-pronged design. First, we compared indices of
LDF with standard Framingham and Cardiorisk CV risk assessment
systems. Second, we performed a longitudinal prospective cohort
study on all subjects over up to 2 years follow-up.
We studied 70 male and female ESRD patients between the ages
of 24 and 86 with renal failure, who were attending our dialysis unit.
Patients examined had no surgical procedures on the limb used for
investigation. Subjects had no food intake for at least 2 h, did not
take their morning medications and smokers were asked to abstain
from smoking for at least 3 h prior to the testing. Exclusion criteria
were as follows: psoriasis, peripheral neuropathy, liver failure,
neoplastic disease, Cushing’s syndrome, collagen vascular disease,
dermatological problems, chronic angioedema, or lymphedema,
uncontrolled hyperthyroidism, chronic substance abuse, or any
condition precluding the subjects completion of the protocol. The
Committee for the Protection of Human Subjects (IRB) at New York
Medical College approved this study, and all examined individuals
read and signed an informed consent.
Controls were healthy male and female subjects, who were age-
matched to ESRD patients. Control subjects were enrolled with
exclusion criteria similar to ESRD patients except that controls had
no ESRD, chronic kidney disease, CV disease, or diabetes. Neither
cases nor controls were taking neurally active or vasoactive
medications on the morning of study.
Testing was performed prior to dialysis in a temperature-
controlled room kept at 241C with a relative humidity of 40%. All
tests were performed while subjects sat in a comfortable armchair.
Following a 30-min acclimatization period, we measured blood
pressure and heart rate, and subjects were acclimated to the laser
equipment, monitoring equipment, and environment. The arm
selected for investigations had no graft or fistula. It was positioned at
heart level and gently immobilized using a vacuum pillow contain-
ing polyurethane beads, which moulds to the shape of the arm
(Germa, Sweden). Two areas of the volar aspect of the forearm were
chosen: one a 2 2 cm2 site for laser-Doppler perfusion imaging
(Perimed PeriScan PIM II, Stockholm, Sweden), with each scan
taking approximately ten seconds; a second site spaced approxi-
mately 6 cm from the scanning site was used to continuously
measure skin blood perfusion using a laser-Doppler perfusion
monitor (LDPM) with single-point LDF probes (Perimed Periflux
System 5000, Stockholm, Sweden). Continuous LDPM employed
coherent laser light at a wavelength of 780 nm, which was sampled at
a rate of 32 samples per second. LDF was measured in arbitrary
perfusion units (PFU). Sampled LDF was interfaced to a personal
computer through an A/D converter (DATAQ) using PeriSoft data
acquisition software. LDPM data were electronically readjusted such
that baseline flow fell on the Y-axis for perfusion units and changes
in LDF were measured thereafter. We applied two types of challenges
to the cutaneous microcirculation: an arterial occlusion cuff and
local hyperthermia and measured LDPM during postobstructive
reactive hyperemia (PORH) and TH, respectively (Figure 11).
PORH
Following the acclimatization period, baseline LDPM and laser-
Doppler perfusion imaging of the forearm were recorded. An
occlusion cuff placed around the upper arm was inflated to a
pressure 15 mm Hg above the systolic pressure for 4 min. The
absence of cutaneous flow was documented by the LDF. PORH
response (pay-back response) upon release of arterial occlusion was
recorded until full recovery to basal level. The payback response was
quantified by measuring the area under the PORH curve with
respect to the baseline (defined as zero). At the peak of payback
response, laser-Doppler perfusion imaging of the same volar
forearm 2 2 cm2 area was performed. Data analysis was performed
using PeriSoft software (Perimed). We measured peak flow (PFU),
time to peak flow (s), and area under the curve (PFUs).
Local TH. Local heating of nonglabrous skin such as the
forearm evokes vasodilation that is mediated by local neurogenic
reflexes and is almost entirely nitric oxide dependent.11–14 The
LDPM probe was heated to 431C over a 2-min period. Laser-
Doppler flow was measured over the next 30 min to record flow
patterns characterized by an initial peak, followed by a nadir, and
finally rising to a second peak that continues as a sustained
plateau. Kellogg, Johnson and co-workers12 and Minson et al14
showed that the dilator response to local heating is related to nitric
oxide, which plays a major role in the sustained cutaneous
vasodilation (i.e. the secondary plateau) of prolonged heating.
Nitric oxide synthase inhibitors blunt both measured heat peaks
but have a more pronounced effect on the second peak and
plateau.
Cross-sectional risk assessment and statistical analyses
The 10-year CV risk was assessed using both the Framingham
criteria (age, low-density lipoprotein, high-density lipoprotein,
blood pressure, history of diabetes, and history of smoking), and
a newer web based computer program, Cardiorisk10 based on the
Framingham criteria, except for substituting total cholesterol for
low-density lipoprotein. Additional criteria include prior history
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Figure 11 | Laser Doppler parameters and their changes in ESRD
patients. Laser Doppler flow averages of control and ESRD patients
are shown for PORH and thermal hyperemia experiments (7s.d.). The
ESRD average perfusion (green line) is well below that for the control
population (red line) throughout both portions of the experiment.
PORH measurements included (a) amplitude and (b) time to peak as
well as the (c) area under the curve. Thermal hyperemia measure-
ments included (d–f) amplitudes and (g–i) times to first heat peak,
heat nadir and second heat peak, respectively. Additionally, the area
under the curve for the first 30 min of heating was measured.
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of atrial fibrillation, left ventricular hypertrophy and known CV
disease. Data were grouped according to the 10-year risk assessment
(expressed as % risk) using each set of criteria. The patients were
then divided relative to the median into high- and low-risk groups.
Values for each group are expressed as mean7s.e. Mann–Whitney
tests were used to assess significance. Correlations between the
continuous variables and risk scores were estimated using Kendal’s t
for nonparametric distribution. ROC curves were performed using
mROC15 to assess the ability of the combined data to predict CV risk.
Longitudinal risk assessment and statistical analyses
At 2 years after an initial LDF study, CV mortality and surrogate end
points including development of coronary heart disease, myocardial
infarction, cerebrovascular accidents, peripheral arterial disease, and
congestive heart failure were assessed based on the clinical data.
Nonparametric Mann–Whitney test was used to establish the
significance of the contribution of each LDF parameter to the
individual outcome.
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